Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor in CF with Non-G551D Gating Mutations
NCT01614470Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second at 24 weeks. Started Jul 2012; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01614470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614470.